PWM
SRPT icon

Prentice Wealth Management’s Sarepta Therapeutics SRPT Stock Holding History

Prentice Wealth Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-107
Closed -$10K – 276
2021
Q3 		$10K Sell
107
-17
-14% -$1.31K ﹤0.01% 249
2021
Q2 		$10K Sell
124
-6
-5% -$455 0.01% 247
2021
Q1 		$10K Buy
+130
New +$12K 0.01% 250

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Prentice Wealth Management's SRPT Position: Q4 2021 in Review

Prentice Wealth Management sold out of Sarepta Therapeutics (SRPT) in Q4 2021, closing a stake of 107 shares — an estimated $10K sold.

Prentice Wealth Management first reported a position in SRPT in Q1 2021 and held it in 3 quarters. The position peaked at $10K in Q3 2021. 343 funds tracked by Wall St. Rank hold SRPT as of Q4 2021.

  • Prentice Wealth Management reported no remaining Sarepta Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Prentice Wealth Management sold 107 Sarepta Therapeutics shares in Q4 2021, an estimated $10K.
  • Prentice Wealth Management first reported a position in Sarepta Therapeutics in Q1 2021 and held it in 3 quarters.
  • Prentice Wealth Management's Sarepta Therapeutics position peaked at $10K in Q3 2021.
  • 343 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2021.

Based on Prentice Wealth Management's 13F filing for Q4 2021, filed 31 Oct 2022.